An interventional study of Tranexamic acid in Postoperative Bleeding, sponsored by St. Mary's Research Center, Canada. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by St. Mary's Research Center, Canada · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Tranexamic Acid in Postoperative Hemorrhage — 5 open to participants now, 5 under way, 1 of them phase 3. Tranexamic Acid · Postoperative Hemorrhage.
Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 with no phase, and was the 21st registered.
135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.
Browse Postoperative Hemorrhage studies →5 of the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Ascension Health · Sites in United States
Ages 18+ · Healthy volunteers
Clinique Saint-Luc · Sites in Belgium
Ages 18+
Ramathibodi Hospital · Sites in Thailand
Ages 18–50
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 17 Postoperative Hemorrhage studies recruiting now, 11 (65%) set no upper age limit and 4 (24%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 5 · Phase 4 10
First in 2008; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 100 across 102 interventional studies indexed under Postoperative Hemorrhage.
Median enrollment 116 across the 25 interventional studies. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
St. Mary's Research Center, Canada is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
St. Mary's Research Center, Canada has 1 study filed under Postoperative Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies testing Tranexamic Acid in Postoperative Hemorrhage that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06208267St. Mary's Research Center, CanadaTranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty.
The efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide.
This RCT aims to compare the current standard dosing for TXA to additional TXA doses given orally post-operatively for THA and TKA patients. The goal is to compare the following between study groups: visible bleeding on post-operative dressing, mobilization (steps, amount of time moving around), pain (visual analog scale), function (Oxford hip and knee scales) and ROM at four to six weeks.
Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are some of the most common surgical procedures performed in elderly patients, with the main indication being end-stage osteoarthritis. While these procedures can result in a significant amount of bleeding, pain and stiffness post-operatively, they have been increasingly performed as day surgeries and with reduced length of stay.
Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty.
The efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide.
The current standard of care at St-Mary's for TXA use is one gram given intravenously (IV) at the beginning of the replacement and one gram given during cementation. However, despite the established benefits of TXA, the optimal dosing regimen continues to be an area of ongoing research and discussion.
TXA and post-operative hemoglobin and hematocrit levels The use of TXA in knee and hip arthroplasty has been shown to have clear and significant benefits in reducing the post-operative drop in hemoglobin (Hb) and hematocrit (Hct) but the duration of use has ranged from a single pre-operative dose to a prolonged 14-day course. Researchers reported higher post-operative Hb and Hct following THA and TKA using a three-day course of TXA compared to a single pre-operative dose of 1.5g. However another study, showed no added benefit of the addition of a second post-operative dose to the single pre-operative dose. Similarly, an randomized controlled trial (RCT) comparing TXA doses at pre, during and three hours post-operative to the same with additional doses at six and 12 hours and showed no added benefit of the additional two doses on Hb or Hct levels. In contrast to this, three RCTs performed in 2019 and 2021 showed improved Hb and Hct levels with TXA use beyond a minimum of seven hours post-operatively and two involved the use of TXA given by mouth (PO), which is ideal in the ambulatory setting.
TXA and Ambulation/Motion The majority of the studies involving varying doses of TXA following THA and TKA have not assessed articular motion nor ambulation post-operatively. These can have an impact on patient satisfaction as well as the ability to mobilize and be able to leave the hospital earlier. TXA was compared to placebo and demonstrated that patients who received TXA ambulated 20% more during physiotherapy sessions. Several TXA regimens with patients receiving a minimum of three post-operative doses (maximum of four post-operative doses were studied),showed having significantly better range of motion (ROM) than patients who received less. Additionally, these patients reported less post-operative pain.
TXA and Complications
No increase in adverse events were reported in any of these studies following prolonged TXA use. Cardiovascular events, deep vein thrombosis (DVT), pulmonary embolism (PE), renal failure or superficial thrombosis were not different among study groups in the rare cases where they occurred, even with oral TXA given for up to 14 days post-operatively
. At St-Mary's Hospital, we perform a large number of TKAs and THAs, around 1100 per year (600 knees, 500 hips), making us the most productive hospital performing these procedures in Québec. Also, partly driven by the constraints of the pandemic over the past three years, we have successfully and safely reduced the length of stay for our patients and converted hundreds of patients to day surgery. Bleeding, however, remains a significant source of patient anxiety, with 10% of our ambulatory cases needing additional CLSC care or even return to hospital. Rapid mobilization and decrease in post- operative pain are also key factors for a rapid and safe discharge from hospital.
In this RCT, we aim to compare our current standard dosing for TXA to additional TXA doses given orally post-operatively for our THA and TKA patients. We will be the first of this type of study to assess patient mobility using a wearable device that will allow for precise measurement of step counts, amount of time moving around and sleep times. Also new compared to previous studies, will be our assessment of bleeding complications requiring intervention and needs for additional hospital or nursing visits, both of which have and impact on the cost of care. Pain (VAS scale), function (Oxford hip and knee scales) and ROM will also be assessed at 4-6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
° All adults undergoing primary TKA and THA at St-Mary's Hospital
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 gm TA IV given prior to incision and 1G TXA IV during cementation or closure
Drug: Tranexamic acid
Standard + 1G oral TXA given at 0 and 8 hours post-operatively
Drug: Tranexamic acid
Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively
Drug: Tranexamic acid
This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA
Also known as: CYKLOKAPRON
Step counts at 24 and 48 hours post -operative
We hypothesize that patients receiving additional doses of TXA will mobilize more at 24 and 48 hours post- operatively and that this will be dose-dependent.
Time frame: Post-operative
Range of motion (ROM) of the hip (if applicable):
Measuring ROM of the hip taken pre-operatively, post-operatively and 4 to 6 weeks post-operatively if patient received a total hip arthroplasty (THA)
Time frame: 4 - 6 weeks post op
Range of motion (ROM) of the knee (if applicable):
Measuring ROM of the knee taken pre-operatively, post-operatively and 4 to 6 weeks post-operatively if patient received a total knee arthroplasty (TKA).
Time frame: 4 - 6 weeks post op
Patient self-assessment of functionality and pain measured pre-operatively, 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively following total hip arthroplasty utilizing the Oxford Hip Score (OHS):
Minimal value of 0 and maximal value of 48. The higher scores indicate more satisfactory joint function.
Time frame: 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively
Patient self-assessment of functionality and pain measured pre-operatively, 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively following total knee arthroplasty utilizing the Oxford Knee Score (OKS):
joint function.
Time frame: 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively
Bleeding Complications requiring intervention
Bleeding that require a specific intervntion from CLSC/Clinic/Hospital visits
Time frame: Return to the emergency room or bleeding complications will be noted.
Daily step counts
To be measured with an application (MyMobility) on a smartphone or smartwatch used by the patient. This is a numerical value simply describing the number of steps taken by the patient on a day-to-day basis. This measurement will be collected pre-operatively (until OR), on post-operative day 0,1,2,3,5,7 and 4 to 6 weeks postoperatively.
Time frame: Post-operative day 0,1,2,3,5,7 and 4 to 6 weeks postoperatively.
Measure of quality of life using the 12-Item Short Form Survey (SF-12):
Regarding minimum and maximum values, there are two summary scores that are reported from the SF-12: there is a mental component score (MCS-12) and a physical component score (PCS-12). The scores may also be reported as Z-scores where a difference would be compared to the population average. In the literature, SF-12 results have also been computed as a range going from a minimum value of 0 to a maximum value of 100, where higher scores indicate better physical and mental health functioning.
Time frame: This measurement will be taken pre-operatively, 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively.
Assessment and screening for depression and anxiety in patients utilizing the Hospital Anxiety Depression Scale (HADS) :
Minimum score of 0 and maximum score of 21. The higher scores indicate higher distress.
Time frame: Pre-operative
Reported pain self-reported in patient journal and possibly in-patient charts:
This is a numerical value. Patient journals and/or in-patient charts, if applicable, would be screened for frequency of opioid use as a way of evaluating pain management post-operatively.
Time frame: These journals and/or in-patient charts will be verified on postoperative day 0,1,2,3,5 and 7.
Assessment of catastrophic thinking related to pain utilizing the Pain Catastrophizing Scale (PCS):
Minimum score of 0 and maximum score of 52. The higher scores indicate higher levels of catastrophizing.
Time frame: Pre-operative
Reported pain using the visual analog pain (VAS) scale:
The pain VAS scale involves a numerical rating scale or a descriptive rating scale that progressively goes from a minimal value indicating severe pain to a maximal value indicating good pain management.
Time frame: This measurement will be collected on postoperative day 0, 1,2,3,5 and 7.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Apr 2027, 20 months after the start.
Of 35 non-industry interventional studies with no phase under Postoperative Hemorrhage, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 20 months is above that.
Counting every sponsor, half of 38 studies reached it within 14 months; a quarter within 8 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
St. Mary's Research Center, Canada